Steven J. Prestrelski, Ph.D., M.B.A, is seasoned biopharmaceutical executive with over 30 years of scientific and operational expertise who has led successful endocrine and metabolism product development programs from discovery through regulatory approval. Dr. Prestrelski serves as our Chief Scientific Officer.

Dr. Prestrelski previously served as Founder and Chief Scientific Officer at Xeris Biopharma Holdings Inc., a publicly traded pharmaceutical company focused on innovative ready-to-use solutions to improve patients’ lives. During his time at Xeris, he was responsible for all aspects of company research and development and intellectual property operations, portfolio management, and new product development. He also served as the company’s interim Chief Executive Officer from 2013-2014 and served on its board of directors from 2005-2015. Prior to Xeris, Dr. Prestrelski was Vice President, Pharmaceutical Research and Development at Amylin Pharmaceuticals, Inc., where he oversaw its R&D portfolio, including the Bydureon© (GLP-1) program in diabetes and managing the strategic alliances with Eli Lilly and Alkermes. Prior to Amylin, Dr. Prestrelski held significant roles in drug formulation and delivery as Vice President, Biopharmaceuticals at PowderJect Technologies, Inc., and as Director, Biopharmaceuticals at Alza. He also worked as a research scientist at both Amgen and the US Department of Agriculture.

Dr. Prestrelski has published over 60 peer-reviewed journal articles and invited book chapters. He has 35 issued U.S. patents (over 100 globally) and 47 pending patent applications in the field of drug development, formulation, and delivery.

Dr. Prestrelski earned a B.S. in nutrition science from Drexel University, a Ph.D. in molecular biophysics from the City University of New York and an M.B.A. from Rady School of Management at the University of California, San Diego.